Using both our retrospective cohort of clinical samples, and data from The Cancer Genome Atlas (TCGA), we identify TNFRSF4/OX40 and TNFRSF9/4-1BB as two immune markers of potential relevance to sarcoma. This evidence concerns the gene TNFRSF9 and sarcoma.